Merck and Terns Pharmaceuticals have agreed to a $6.7 billion all-cash buyout that delivers a prized leukemia asset to the New Jersey Big Pharma.
- Home |
- Merck, girding for Keytruda cliff, flies toward promising CML asset with $6.7B Terns acquisition
Merck, girding for Keytruda cliff, flies toward promising CML asset with $6.7B Terns acquisition
- March 25, 2026
Recent Posts
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
- Cenovus to build oil sands business via Athabasca acquisition
- Centalion acquires Haynesville gas assets from Silver Hill
- Energy Transfer expands Delaware basin footprint with $2.625 billion deal
